Search

Your search keyword '"Wicklein, Eva-Maria"' showing total 3 results
Start Over Author "Wicklein, Eva-Maria" Topic clinically isolated syndrome
3 results on '"Wicklein, Eva-Maria"'

2. MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry

Author

Bendfeldt, Kerstin, Taschler, Bernd, Gaetano, Laura, Madoerin, Philip, Kuster, Pascal, Mueller-Lenke, Nicole, Amann, Michael, Vrenken, Hugo, Wottschel, Viktor, Barkhof, Frederik, Borgwardt, Stefan, Klöppel, Stefan, Wicklein, Eva-Maria, Kappos, Ludwig, Edan, Gilles, Freedman, Mark S., Montalbán, Xavier, Hartung, Hans-Peter, Pohl, Christoph, Sandbrink, Rupert, Sprenger, Till, Radue, Ernst-Wilhelm, Wuerfel, Jens, and Nichols, Thomas E.

Published
2019
Full Text
View/download PDF

3. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial

Author

Kappos, Ludwig, Edan, Gilles, Freedman, Mark S., Montalbán, Xavier, Hartung, Hans-Peter, Hemmer, Bernhard, Fox, Edward J., Barkhof, Frederik, Schippling, Sven, Schulze, Andrea, Pleimes, Dirk, Pohl, Christoph, Sandbrink, Rupert, Suarez, Gustavo, Wicklein, Eva-Maria, Csiba, László, Csépány, Tünde, University of Basel (Unibas), Vision, Action et Gestion d'informations en Santé (VisAGeS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Inria Rennes – Bretagne Atlantique, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-SIGNAUX ET IMAGES NUMÉRIQUES, ROBOTIQUE (IRISA-D5), Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS), Ottawa Hospital Research Institute [Ottawa] (OHRI), Vall d'Hebron University Hospital [Barcelona], Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Munich Cluster for systems neurology [Munich] (SyNergy), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM)-Ludwig-Maximilians-Universität München (LMU), Virginia Tech [Blacksburg], University hospital of Zurich [Zurich], PAREXEL International [Berlin], VU University Medical Center [Amsterdam], Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Bayer HealthCare Pharmaceuticals Inc [Whippany], Bayer Pharma AG [Berlin], University of Zurich, Kappos, L, Edan, Gilles, CentraleSupélec-Télécom Bretagne-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de Recherche en Informatique et en Automatique (Inria)-École normale supérieure - Rennes (ENS Rennes)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-CentraleSupélec-Télécom Bretagne-Université de Rennes 1 (UR1), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École normale supérieure - Rennes (ENS Rennes)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA), Dubois, Bénédicte, Department of Neurology [Suisse], University Hospital Basel [Basel], Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-CentraleSupélec-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Université de Rennes (UNIV-RENNES)-CentraleSupélec-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Rennes (ENS Rennes)-Télécom Bretagne-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-CentraleSupélec, Service de Neurologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], The Ottawa Hospital, Medical Image Analysis Center (MIAC AG), Department of neurology, Heinrich-Heine-Universität Düsseldorf [Düsseldorf], Munich Cluster of Systems Neurology (SyNery), Department Neurology of the Klinikum rechts der Isar, Technische Universität München [München] (TUM), Myelo Therapeutics [Berlin], Consejo Nacional de Investigaciones Científicas y Técnicas [Buenos Aires] (CONICET), Klinische Neurowetenschappen, MUMC+: MA Med Staf Spec Neurologie (9), RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Technische Universität München [München] (TUM)-Ludwig-Maximilians-Universität München (LMU), Radiology and nuclear medicine, and Amsterdam Neuroscience - Neuroinfection & -inflammation

Subjects
0301 basic medicine, Male, Cross-sectional study, MESH: Adjuvants, Immunologic, Kaplan-Meier Estimate, Disability Evaluation, 0302 clinical medicine, Recurrence, Medicine, MESH: Double-Blind Method, Young adult, 10. No inequality, MESH: Treatment Outcome, Clinically isolated syndrome, MESH: Disability Evaluation, Orvostudományok, MESH: Follow-Up Studies, 3. Good health, Treatment Outcome, 2728 Neurology (clinical), MESH: Young Adult, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Interferon beta-1b, Adult, medicine.medical_specialty, Randomization, MESH: Demyelinating Diseases, 610 Medicine & health, MESH: Interferon beta-1b, Placebo, Klinikai orvostudományok, Article, Time-to-Treatment, 03 medical and health sciences, Young Adult, MESH: Cross-Sectional Studies, Adjuvants, Immunologic, Double-Blind Method, Immunologic/administration & dosage* Adult Cross-Sectional Studies Demyelinating Diseases/diagnostic imaging Demyelinating Diseases/drug therapy* Disability Evaluation Double-Blind Method Female Follow-Up Studies Humans Interferon beta-1b/administration & dosage* Kaplan-Meier Estimate Male Recurrence Time-to-Treatment Treatment Outcome Young Adult, Internal medicine, Humans, Adjuvants, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], MESH: Time-to-Treatment, MESH: Kaplan-Meier Estimate, Expanded Disability Status Scale, MESH: Humans, business.industry, Multiple sclerosis, MESH: Adult, medicine.disease, MESH: Male, Surgery, 10040 Clinic for Neurology, MESH: Recurrence, 030104 developmental biology, Cross-Sectional Studies, Neurology (clinical), business, MESH: Female, 030217 neurology & neurosurgery, Demyelinating Diseases, Follow-Up Studies
Abstract

Objective: To assess outcomes for patients treated with interferon beta-1b immediately after clinicallyisolated syndrome (CIS) or after a short delay.Methods: Participants in BENEFIT (Betaferon/Betaseron in Newly Emerging MS for Initial Treatment)were randomly assigned to receive interferon beta-1b (early treatment) or placebo (delayedtreatment). After conversion to clinically definite multiple sclerosis (CDMS) or 2 years, patients onplacebo could switch to interferon beta-1b or another treatment. Eleven years after randomization,patients were reassessed.Results: Two hundred seventy-eight (59.4%) of the original 468 patients (71.3% of those eligible atparticipating sites) were enrolled (early: 167 [57.2%]; delayed: 111 [63.1%]). After 11 years, risk ofCDMS remained lower in the early-treatment arm compared with the delayed-treatment arm (p 50.0012), with longer time to first relapse (median [Q1, Q3] days: 1,888 [540, not reached] vs 931[253, 3,296]; p50.0005) and lower overall annualized relapse rate (0.21 vs 0.26; p50.0018). Only25 patients (5.9%, overall; early, 4.5%; delayed, 8.3%) converted to secondary progressive multiplesclerosis. Expanded Disability Status Scale scores remained low and stable, with no differencebetween treatment arms (median [Q1,Q3]: 2.0 [1.0, 3.0]). The early-treatment group had better PacedAuditory Serial Addition Task–3 total scores (p 5 0.0070). Employment rates remained high, andhealth resource utilization tended to be low in both groups.MRI metrics did not differ between groups.Conclusions: Although the delay in treatment was relatively short, several clinical outcomesfavored earlier treatment. Along with low rates of disability and disease progression in bothgroups, this supports the value of treatment at CIS., NCT01795872.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results